Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

HDL cholesterol: reappraisal of its clinical relevance.

März W, Kleber ME, Scharnagl H, Speer T, Zewinger S, Ritsch A, Parhofer KG, von Eckardstein A, Landmesser U, Laufs U.

Clin Res Cardiol. 2017 Mar 24. doi: 10.1007/s00392-017-1106-1. [Epub ahead of print] Review.

2.

Effects of Dietary Flavonoids on Reverse Cholesterol Transport, HDL Metabolism, and HDL Function.

Millar CL, Duclos Q, Blesso CN.

Adv Nutr. 2017 Mar 15;8(2):226-239. doi: 10.3945/an.116.014050. Print 2017 Mar. Review.

PMID:
28298268
3.

Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.

Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJ, Merkely B, Nissen SE, Ray K, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Butters J, Girardi J, Miller R, Nicholls SJ.

Cardiovasc Diagn Ther. 2017 Feb;7(1):45-51. doi: 10.21037/cdt.2017.01.01.

4.

Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis.

Di Bartolo BA, Schwarz N, Andrews J, Nicholls SJ.

Arch Med Sci. 2017 Feb 1;13(1):210-214. doi: 10.5114/aoms.2016.60941. Epub 2016 Jun 30.

5.

Human Neutrophil Peptide 1 Limits Hypercholesterolemia-induced Atherosclerosis by Increasing Hepatic LDL Clearance.

Paulin N, Döring Y, Kooijman S, Blanchet X, Viola JR, de Jong R, Mandl M, Hendrikse J, Schiener M, von Hundelshausen P, Vogt A, Weber C, Bdeir K, Hofmann SM, Rensen PC, Drechsler M, Soehnlein O.

EBioMedicine. 2017 Feb;16:204-211. doi: 10.1016/j.ebiom.2017.01.006. Epub 2017 Jan 7.

6.

Local Vascular Gene Therapy With Apolipoprotein A-I to Promote Regression of Atherosclerosis.

Wacker BK, Dronadula N, Zhang J, Dichek DA.

Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):316-327. doi: 10.1161/ATVBAHA.116.308258. Epub 2016 Dec 8.

PMID:
27932352
7.

Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond.

Di Bartolo BA, Scherer DJ, Nicholls SJ.

Arch Med Sci. 2016 Dec 1;12(6):1302-1307. Epub 2016 Oct 24.

8.

Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio.

Kaul S, Xu H, Zabalawi M, Maruko E, Fulp BE, Bluemn T, Brzoza-Lewis KL, Gerelus M, Weerasekera R, Kallinger R, James R, Zhang YS, Thomas MJ, Sorci-Thomas MG.

J Am Heart Assoc. 2016 Nov 7;5(11). pii: e004401.

9.

The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications.

Feig JE, Feig JL, Dangas GD.

Coron Artery Dis. 2016 Nov;27(7):592-603. doi: 10.1097/MCA.0000000000000408. Review.

PMID:
27414247
10.

In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models.

Pérez-Medina C, Binderup T, Lobatto ME, Tang J, Calcagno C, Giesen L, Wessel CH, Witjes J, Ishino S, Baxter S, Zhao Y, Ramachandran S, Eldib M, Sánchez-Gaytán BL, Robson PM, Bini J, Granada JF, Fish KM, Stroes ES, Duivenvoorden R, Tsimikas S, Lewis JS, Reiner T, Fuster V, Kjær A, Fisher EA, Fayad ZA, Mulder WJ.

JACC Cardiovasc Imaging. 2016 Aug;9(8):950-61. doi: 10.1016/j.jcmg.2016.01.020. Epub 2016 May 25.

11.

ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia.

Cubedo J, Padró T, Alonso R, Mata P, Badimon L.

J Lipid Res. 2016 Jun;57(6):1059-73. doi: 10.1194/jlr.P061598. Epub 2016 Apr 25.

12.

Micro-RNAs and High-Density Lipoprotein Metabolism.

Canfrán-Duque A, Lin CS, Goedeke L, Suárez Y, Fernández-Hernando C.

Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1076-84. doi: 10.1161/ATVBAHA.116.307028. Epub 2016 Apr 14. Review.

13.

New Era of Lipid-Lowering Drugs.

Barter PJ, Rye KA.

Pharmacol Rev. 2016 Apr;68(2):458-75. doi: 10.1124/pr.115.012203. Review.

14.

miRNAs and High-Density Lipoprotein metabolism.

Baldán Á, de Aguiar Vallim TQ.

Biochim Biophys Acta. 2016 Dec;1861(12 Pt B):2053-2061. doi: 10.1016/j.bbalip.2016.01.021. Epub 2016 Feb 9.

PMID:
26869447
15.

High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need.

Cimmino G, Ciccarelli G, Morello A, Ciccarelli M, Golino P.

Transl Med UniSa. 2014 Sep 1;12:29-40. eCollection 2015 May-Aug.

16.

Non-clinical development of CER-001.

Barbaras R.

Front Pharmacol. 2015 Oct 6;6:220. doi: 10.3389/fphar.2015.00220. eCollection 2015. Review.

17.

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis.

Chyu KY, Shah PK.

Front Pharmacol. 2015 Sep 1;6:187. doi: 10.3389/fphar.2015.00187. eCollection 2015. Review.

18.

HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE-/- Mice: Evidence of ABCA1 Down-Regulation.

Tardy C, Goffinet M, Boubekeur N, Cholez G, Ackermann R, Sy G, Keyserling C, Lalwani N, Paolini JF, Dasseux JL, Barbaras R, Baron R.

PLoS One. 2015 Sep 3;10(9):e0137584. doi: 10.1371/journal.pone.0137584. eCollection 2015.

19.

A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients.

Cubedo J, Padró T, García-Arguinzonis M, Vilahur G, Miñambres I, Pou JM, Ybarra J, Badimon L.

J Lipid Res. 2015 Sep;56(9):1762-73. doi: 10.1194/jlr.P057513. Epub 2015 Jul 13.

20.

The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties.

Schwendeman A, Sviridov DO, Yuan W, Guo Y, Morin EE, Yuan Y, Stonik J, Freeman L, Ossoli A, Thacker S, Killion S, Pryor M, Chen YE, Turner S, Remaley AT.

J Lipid Res. 2015 Sep;56(9):1727-37. doi: 10.1194/jlr.M060285. Epub 2015 Jun 27.

Supplemental Content

Support Center